Side-by-side · Research reference

FOXO4-DRIvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BFDA-ApprovedFlagship14/45 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

FOXO4-DRI

Tirzepatide

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

—

Glucose-dependent insulin release preserves physiological feedback

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

Tirzepatide

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Route

SQ (animal)

No human route established.

—

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Indefinite for chronic indication

Clinical status

No human trials completed

—

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

Reconstitution

—

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

Timing

—

Once weekly, any time of day

Half-life

—

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

04Side Effects & Safety

Parameter

FOXO4-DRI

Tirzepatide

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

Contraindicated

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

FOXO4-DRI

Tirzepatide

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

Pen-supplied. Research vial: 27–31G insulin syringe.